Manufacturer’s reply to letter by Seed and colleagues

[...]the placebo in clinical trials with tiotropium Respimat was identical to the active treatment except for the lack of the active chemical entity. [...]the concentration of benzalkonium chloride in Respimat solutions (100 [micro]g/mL) is within the range typically used in nebuliser solutions.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ 2011-08, Vol.343 (aug23 4), p.d5365-d5365
Hauptverfasser:	Disse, Bernd, Metzdorf, Norbert, Bender, Helmut
Format:	Artikel
Sprache:	eng
Schlagworte:	Asthma Bronchodilator Agents - adverse effects Chloride Chronic obstructive pulmonary disease Clinical trials Humans Respiratory therapy Scopolamine Derivatives - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	[...]the placebo in clinical trials with tiotropium Respimat was identical to the active treatment except for the lack of the active chemical entity. [...]the concentration of benzalkonium chloride in Respimat solutions (100 [micro]g/mL) is within the range typically used in nebuliser solutions.
ISSN:	0959-8138 1468-5833 1756-1833
DOI:	10.1136/bmj.d5365